CoChat

A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity

Open access

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

Abstract

Mazdutide is a once-weekly glucagon-like peptide-1 (GLP-1) and glucagon receptor dual agonist. We evaluated the efficacy and safety of 24-week treatment of mazdutide up to 6 mg in Chinese overweight adults or adults with obesity, as an interim analysis of a randomised, two-part (low doses up to 6 mg and high dose of 9 mg), double-blind, placebo-controlled phase 2 trial (ClinicalTrials.gov, NCT04904913). Overweight adults (body-mass index [BMI] ≥24 kg/m 2 ) accompanied by hyperphagia and/or at least one obesity-related comorbidity or adults with obesity (BMI ≥ 28 kg/m 2 ) were randomly assigned (3:1:3:1:3:1) to once-weekly mazdutide 3 mg, 4.5 mg, 6 mg or matching placebo at 20 hospitals in China. The primary endpoint was the percentage change from baseline to week 24 in body weight. A total of 248 participants were randomised to mazdutide 3 mg ( n = 62), 4.5 mg ( n = 63), 6 mg ( n = 61) or placebo ( n = 62). The mean percentage changes from baseline to week 24 in body weight were −6.7% (SE 0.7) with mazdutide 3 mg, −10.4% (0.7) with 4.5 mg, −11.3% (0.7) with 6 mg and 1.0% (0.7) with placebo, with treatment difference versus placebo ranging from −7.7% to −12.3% (all p < 0.0001). All mazdutide doses were well tolerated and the most common adverse events included diarrhoea, nausea and upper respiratory tract infection. In summary, in Chinese overweight adults or adults with obesity, 24-week treatment with mazdutide up to 6 mg was safe and led to robust and clinically meaningful body weight reduction.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-023-44067-4

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Trial profile. The flow diagram shows the disposition of participants screened and enrolled.
Fig. 1 Trial profile. The flow diagram shows the disposition of participants screened and enrolled.CC BY · PubMed Central
Fig. 2 Body weight efficacy endpoints. a Percentage change from baseline in body weight at week 24. Symbols and error bars represent LSM and SE, from the primary analysis for the primary endpoint (ANCOVA + LOCF), mITT population. Numbers are LSM. Violin plots represent observed percentage changes from baseline in body weight for participants in the mITT population. b Percentage change from baseline in body weight over time. Symbols and error bars represent LSM and SE, from the sensitivity analysis for the primary endpoint (MMRM), mITT population. Numbers are LSM. c Change from baseline in body weight at week 24. Symbols and error bars represent LSM and SE, from MMRM analysis, mITT population. Numbers are LSM. Violin plots represent observed changes from baseline in body weight for participants in the mITT population. d Proportion of participants reaching weight loss targets (≥5% and ≥10%), mITT population. Mazdutide 3 mg n = 62; mazdutide 4.5 mg n = 63; mazdutide 6 mg n = 61; placebo n = 62. ANCOVA analysis of covariate. LOCF last observation carried forward. LSM least squares mean. MMRM mixed model repeated measures. SE standard error. Source data are provided with this paper.
Fig. 2 Body weight efficacy endpoints. a Percentage change from baseline in body weight at week 24. Symbols and error bars represent LSM and SE, from the primary analysis for the primary endpoint (ANCOVA + LOCF), mITT population. Numbers are LSM. Violin plots represent observed percentage changes from baseline in body weight for participants in the mITT population. b Percentage change from baseline in body weight over time. Symbols and error bars represent LSM and SE, from the sensitivity analysis for the primary endpoint (MMRM), mITT population. Numbers are LSM. c Change from baseline in body weight at week 24. Symbols and error bars represent LSM and SE, from MMRM analysis, mITT population. Numbers are LSM. Violin plots represent observed changes from baseline in body weight for participants in the mITT population. d Proportion of participants reaching weight loss targets (≥5% and ≥10%), mITT population. Mazdutide 3 mg n = 62; mazdutide 4.5 mg n = 63; mazdutide 6 mg n = 61; placebo n = 62. ANCOVA analysis of covariate. LOCF last observation carried forward. LSM least squares mean. MMRM mixed model repeated measures. SE standard error. Source data are provided with this paper.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 22 references

Research works printed but not linked: 1

  1. Rosenstock, J., Blueher, M., Schmid, B., Hoefler, J. & Hennige, A. Multiple dose-ranging study of the novel glucagon/GLP-1 receptor dual agonist BI 456906 vs placebo and open-label weekly semaglutide reference control in type 2 diabetes. in. DIABETOLOGIA 65, S314–S315 (2022).

Cited by

See all 134

Metadata

Authors
Ji, L., Jiang, H., Cheng, Z., Qiu, W., Liao, L., Zhang, Y., Li, X., Pang, S., Zhang, L., Chen, L., Yang, T., Li, Y., Qu, S., Wen, J., Gu, J., Deng, H., Wang, Y., Li, L., Han-Zhang, H., Ma, Q., & Qian, L.
Affiliations
  • Peking University People's Hospital (CN)
  • Henan University of Science and Technology (CN)
  • Harbin Medical University (CN)
  • Huzhou Central Hospital (CN)
  • Shandong Provincial QianFoShan Hospital (CN)
  • Jiangxi Pingxiang People's Hospital (CN)
  • First Affiliated Hospital of Bengbu Medical College (CN)
  • Jinan Central Hospital (CN)
  • Second Hospital of Hebei Medical University (CN)
  • Tianjin Medical University (CN)
  • Jiangsu Province Hospital (CN)
  • Tongji University (CN)
  • Innovent Biologics (China) (CN)
Corresponding author
  • Ji, Linong
  • Qian, Lei
Venue
Nature Communications
Published
2023-12-14
Volume
14
Issue
1
Pages
8289-8289
ISSN
2041-1723 (ISSN-L)
OpenAlex
W4389741339
Cited by
118
References
22
Citations by year
2026: 42 · 2025: 47 · 2024: 28 · 2023: 1
FWCI
18.31
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
Innovent Biologics, Inc.
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
Keywords
mazdutide, GLP-1 receptor agonists, glucagon receptor agonist, dual agonist, obesity, overweight, weight loss, hyperphagia, obesity-related comorbidities, drug safety, Chinese adults
MeSH terms
Adult, Body Weight, Diabetes Mellitus, Type 2, Double-Blind Method, Humans, Hypoglycemic Agents, Obesity, Peptides, Treatment Outcome, Overweight, Glucagon-Like Peptide 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity. https://app.cochat.ai/papers/10.1038/s41467-023-44067-4
The paper
Ji, L., Jiang, H., Cheng, Z., Qiu, W., Liao, L., Zhang, Y., Li, X., Pang, S., Zhang, L., Chen, L., Yang, T., Li, Y., Qu, S., Wen, J., Gu, J., Deng, H., Wang, Y., Li, L., Han-Zhang, H., . . . Qian, L. (2023). A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity. Nature Communications. https://doi.org/10.1038/s41467-023-44067-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.